(Reuters) – The U.S. Food and Drug Administration has approved Johnson & Johnson’s multiple sclerosis (MS) treatment, Ponvory, the company said on Friday.
The approval was granted to the U.S. drugmaker’s subsidiary Janssen Pharmaceutical Companies.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Shailesh Kuber)
